Cure My Disease

Don't miss your cure!

 Log in / Sign up

Placental protein clues may unlock mystery of poor fetal growth

NCT ID NCT07701837

Knowledge-focused Sponsor: Samsun University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study examines whether placentas from pregnancies with intrauterine growth restriction (IUGR) have different levels of certain progesterone receptors compared to healthy pregnancies. Researchers will analyze placental tissue collected after delivery from 90 women. The goal is to better understand the biological causes of IUGR, which affects fetal growth.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If this study finds clear differences in receptor levels, it could point toward new ways to detect or manage intrauterine growth restriction.
What could go wrong
This is a small observational study, not a treatment trial. It can show associations but cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

110 people

The number who actually took part.

Started

Aug 2025

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Pregnant women aged 18-45 years delivering at Samsun Training and Research Hospital will be enrolled. The study population will consist of singleton pregnancies with suspected fetal growth impairment and healthy pregnancies with appropriate fetal growth. Before biomarker analyses, pregnancies with suspected fetal growth impairment will be classified according to the Delphi consensus definition and ISUOG Practice Guidelines into fetal growth restriction (FGR) or small for gestational age (SGA). The final study cohort consists of three groups: FGR, SGA, and healthy controls. Placental tissue samples will be collected immediately after delivery for molecular analysis.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: FGR Group * Pregnant women aged ≥18 years. * Singleton pregnancy. * Gestational age ≥24 weeks. * Diagnosis of fetal growth restriction according to the Delphi consensus criteria (or your institutional protocol if that is what was used in the study). * Planned delivery at the participating hospital. * Written informed consent. SGA Group * Pregnant women aged ≥18 years. * Singleton pregnancy. * Estimated fetal weight or birth weight \<10th percentile without evidence of fetal growth restriction. * Planned delivery at the participating hospital. * Written informed consent Control Group * Pregnant women aged ≥18 years. * Singleton pregnancy. * Appropriate-for-gestational-age fetus (birth weight between the 10th and 90th percentile). * No maternal or fetal complications affecting fetal growth. * Planned delivery at the participating hospital. * Written informed consent. Exclusion Criteria: * Multiple pregnancy. * Major fetal structural or chromosomal anomalies. * Congenital fetal infection. * Known genetic syndromes. * Intrauterine fetal demise. * Maternal malignancy. * Chronic inflammatory or autoimmune disease. * Refusal or inability to provide informed consent. * Inadequate maternal blood or placental sample for analysis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fetal growth restriction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fetal growth restriction placenta disorder placental insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fetal growth restriction PGRMC1 PGRMC2 Placenta Placental dysfunction Pregnancy Progesterone membrane receptor

Contacts and locations

Locations

  • Canan Soyer Çalışkan

    Samsun, Turkey (Türkiye)

  • Samsun University Faculty of Medicine Samsun Training and Research Hospital

    Samsun, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.